少精子症 中国就医指南

Oligospermia is a male fertility disorder characterized by an abnormally low sperm concentration in the ejaculate—defined by the World Health Organization (WHO) as fewer than 15 million sperm per milliliter of semen. It is distinct from azoospermia (complete absence of sperm) and asthenozoospermia (reduced motility) but often co-occurs with other semen parameter abnormalities. The pathogenesis of oligospermia is multifactorial, involving disruptions at various levels of spermatogenesis: pretesticular (e.g., hypothalamic-pituitary axis dysfunction due to hyperprolactinemia, hypogonadotropic hypogonadism, or exogenous testosterone use), testicular (e.g., varicocele, cryptorchidism, genetic conditions like Klinefelter syndrome or Y-chromosome microdeletions, orchitis, or chemotherapy/radiation exposure), and post-testicular (e.g., obstructive causes such as congenital bilateral absence of the vas deferens or prior vasectomy). Oxidative stress, mitochondrial dysfunction, epigenetic alterations, and chronic systemic inflammation also contribute significantly to impaired sperm production and maturation. Epidemiologically, oligospermia affects approximately 30–40% of infertile men globally and is implicated in up to 20% of all couple infertility cases. Prevalence estimates in general male populations range from 5% to 12%, with higher incidence observed in urban, industrialized regions—potentially linked to environmental endocrine disruptors, sedentary lifestyles, and rising obesity rates. Key modifiable risk factors include smoking, excessive alcohol consumption, recreational drug use (especially anabolic steroids and cannabis), obesity (BMI ≥30), prolonged scrotal heat exposure (e.g., saunas, tight underwear, laptop use on lap), occupational exposures (pesticides, heavy metals, solvents), and chronic stress. Non-modifiable risks encompass advanced paternal age (>40 years), genetic predispositions, and prior childhood illnesses affecting testicular development. Beyond reproductive implications, oligospermia frequently correlates with broader health concerns—including metabolic syndrome, cardiovascular disease, type 2 diabetes, and reduced testosterone levels—suggesting it may serve as an early biomarker of systemic male health decline. Psychologically, affected individuals commonly experience diminished self-esteem, anxiety, relationship strain, sexual dissatisfaction, and depression; many report avoidance of social situations involving children or family planning discussions. Quality of life assessments consistently show lower scores in domains of emotional well-being, vitality, and social functioning compared to fertile peers. Importantly, oligospermia is not synonymous with irreversible infertility: many cases respond favorably to targeted interventions—including lifestyle optimization, hormonal therapy, surgical correction (e.g., varicocelectomy), or assisted reproductive technologies (ART)—making timely diagnosis and multidisciplinary management in specialized reproductive medicine departments essential for both fertility restoration and long-term health outcomes.

# 少精子症治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

• •适用人群：精液浓度1–5×10⁶/mL、无梗阻性病因、激素水平轻度异常者
• •药物治疗（3–6个月疗程）：

- 进阶档（hCG+hMG联合抗氧化剂）：8,500–12,000元（含睾丸超声、遗传学筛查、动态精液监测）

• •生活方式干预+中医调理：1,200–3,000元（含体质辨识、针灸12次、中药颗粒剂）

二、手术/微创介入方案

• •适用人群：精索静脉曲张Ⅱ°以上、输精管吻合术适应证、显微取精候选者
• •精索静脉高位结扎术（腹腔镜/显微）：18,000–26,000元（含术前精液分析、阴囊超声、凝血功能、麻醉评估）
• •显微睾丸取精术（mTESE）：32,000–45,000元（含术前FSH、染色体核型、Y微缺失检测，术中冰冻病理）

三、复杂/耐药/并发症方案

• •遗传性少精子症（如AZFc缺失）+ART助孕：65,000–98,000元（含ICSI、胚胎植入前遗传学检测PGT-A）
• •重度氧化应激合并慢性附睾炎：22,000–35,000元（含精浆弹性蛋白酶、ROS检测、靶向抗炎灌注治疗）

四、方案快速选择指南

• •预算≤5,000元：首选药物+生活方式干预（初筛后适用）
• •预算15,000–30,000元+存在静脉曲张：推荐显微结扎术
• •精液持续＜1×10⁶/mL或多次治疗无效：直接评估mTESE+ICSI路径
• •已确诊Y染色体缺失或Klinefelter综合征：建议PGT-A联合供精人工授精（AID）替代方案